IPO’s 2026 Draft Pharma Patent Guidelines Face Legal Scrutiny
The IPO’s Draft Guidelines for Pharmaceutical Patents (2026) face criticism for misquoting statutes and misinterpreting Indian patent law. Experts call for urgent revision to prevent disruption.






